Apogee Therapeutics Inc Analyst Price Targets

Wall Street analyst price targets and consensus rating for Apogee Therapeutics Inc (APGE).

Price Target Range — 10 Quarters

Analyst Consensus — 17 Analysts

5Buy

12Hold

Consensus RatingBuy# Analysts17Avg. Consensus PT$120Upside to Avg. PT-11.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 13, 2026	Truist Securities	Danielle Brill	PT Raise	Hold	$81→$135
Aug 12, 2026	BTIG	Julian Harrison	Downgrade	Buy→Neutral	—
Jun 24, 2026	Stifel	Akash Tewari	Downgrade	Buy→Hold	$133→$135
Jun 24, 2026	TD Cowen	Tyler Van Buren	Downgrade	Buy→Hold	—
Jun 24, 2026	Guggenheim	Seamus Fernandez	Downgrade	Buy→Neutral	—
Jun 24, 2026	Mizuho	Joseph Catanzaro	Downgrade	Outperform→Neutral	$110→$135
Jun 23, 2026	Deutsche Bank	David Hoang	Downgrade	Buy→Hold	$116→$135
Jun 23, 2026	Citigroup	Geoff Meacham	Downgrade	Buy→Neutral	$125→$135
Jun 23, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$97→$135
Jun 23, 2026	UBS	Michael Yee	Downgrade	Buy→Neutral	$100→$135
Jun 23, 2026	Wedbush	David Nierengarten	Downgrade	Outperform→Neutral	$135
Jun 22, 2026	Canaccord Genuity	Edward Nash	Downgrade	Buy→Hold	$130→$135
Jun 8, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$82→$97
May 27, 2026	Truist Securities	Danielle Brill	PT Cut	Hold	$83→$81
May 27, 2026	BTIG	Julian Harrison	Maintained	Buy	$137
May 27, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$120→$135
May 1, 2026	Rothschild & Co	Qize Ding	Initiate	Buy	$140
Mar 30, 2026	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$105→$110
Mar 24, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$95→$125
Mar 24, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$89→$130